Variations in tumor growth, intra-individual biological variability, and the interpretation of changes-Reference-Cited by-同舟云学术

Variations in tumor growth, intra-individual biological variability, and the interpretation of changes

Published:2024-02-19 Issue:8 Volume:62 Page:1618-1625
ISSN:1434-6621
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Trapé Jaume¹²³,Bérgamo Silvia¹²⁴,González-Fernández Carolina¹⁵,Rives José¹,González-García Laura¹²

Affiliation:

1. Laboratory Medicine Department , Althaia Xarxa Assistencial Universitària de Manresa , Manresa , Catalonia , Spain

2. Tissue Repair and Regeneration Laboratory (TR2Lab), Centre for Health and Social Care Research (CESS) , University of Vic – Central University of Catalonia, Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IRIS-CC) , Vic , Spain

3. Faculty of Medicine , University of Vic – Central University of Catalonia , Vic , Spain

4. Doctoral School , University of Vic – Central University of Catalonia , Vic , Spain

5. Gastrointestinal Oncology, Endoscopy and Surgery research group (GOES) , Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IRIS-CC) , Vic , Spain

Abstract

Abstract Objectives The identification of changes in tumor markers (TMs) in cancer patients that indicate response to treatment, stabilization or disease progression is a challenge for laboratory medicine. Several approaches have been proposed: assessing percentage increases, applying discriminant values, and estimating half-life (t1/2) or doubling time (DT). In all of them it is assumed that the TM is a surrogate of the variation in tumor size. In general this variation is time-dependent, but this is not the case of intraindividual biological variability (CVi), which can range from 6 % in CA15-3 to 22 % in CA125. When decisions are made on the basis of DT or t1/2, these values can be affected by the CVi; if it is very large, the growth rate very slow and the period of time between determinations very short, the result obtained for DT may be due mainly to the CVi. The aim of this study is to establish the relationship between the CVi and temporal variables. Methods We related equations for calculating DT and t1/2 to the reference change values in tumor markers. Results The application of the formula obtained allows the calculation of the optimal time between measurements to ensure that the influence of the CVi is minimal in different types of tumors and different scenarios. Conclusions Intraindividual variation affects the calculation of DT and t1/2. It is necessary to establish the minimum time between two measurements to ensure that the CVi does not affect their calculation or lead to misinterpretation.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2023-0780/pdf

Reference25 articles.

1. Benson, AB, Venook, AP, Al-Hawary, MM, Arain, MA, Chen, YJ, Ciombor, KK, et al.. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network 2021;19:329–59. https://doi.org/10.6004/jnccn.2021.0012.

2. Cornford, P, van den Bergh, RCN, Briers, E, Van den Broeck, T, Cumberbatch, MG, De Santis, M, et al.. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 2021;79:263–82. https://doi.org/10.1016/j.eururo.2020.09.046.

3. Scher, HI, Morris, MJ, Stadler, WM, Higano, C, Basch, E, Fizazi, K, et al.. Prostate cancer clinical trials working group 3. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 2016;34:1402–18. https://doi.org/10.1200/jco.2015.64.2702.

4. Sturgeon, CM, Duffy, MJ, Stenman, UH, Lilja, H, Brünner, N, Chan, DW, National Academy of Clinical Biochemistry, et al.. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11–79. https://doi.org/10.1373/clinchem.2008.105601.

5. Bast, RCJr, Ravdin, P, Hayes, DF, Bates, S, Fritsche, HJr, Jessup, JM, American Society of Clinical Oncology Tumor Markers Expert Panel, et al.. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–78. https://doi.org/10.1200/jco.2001.19.6.1865.